Ignite Creation Date:
2024-05-06 @ 4:46 PM
Last Modification Date:
2024-10-26 @ 2:15 PM
Study NCT ID:
NCT05081167
Status:
COMPLETED
Last Update Posted:
2024-03-26
First Post:
2021-10-04
Brief Title:
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder MDD
Sponsor:
Relmada Therapeutics Inc
Organization:
Relmada Therapeutics Inc
Study Overview
Official Title:
A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 Monotherapy for Major Depressive Disorder
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
NCT06009003
Has Expanded Access, NCT# Status:
AVAILABLE
Acronym:
Reliance III
Brief Summary:
This is an outpatient 2-arm Phase 3 multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of REL-1017 once daily QD as a monotherapy for Major Depressive Disorder
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None